The DOI matches its Crossref record; 158 of the 158 references it cites were found in a registry or an index.
Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy
Open accessAbstract
The PI3K pathway is hyperactivated in most cancers, yet the capacity of PI3K inhibitors to induce tumor cell death is limited. The efficacy of PI3K inhibition can also derive from interference with the cancer cells' ability to respond to stromal signals, as illustrated by the approved PI3Kδ inhibitor idelalisib in B-cell malignancies. Inhibition of the leukocyte-enriched PI3Kδ or PI3Kγ may unleash antitumor T-cell responses by inhibiting regulatory T cells and immune-suppressive myeloid cells. Moreover, tumor angiogenesis may be targeted by PI3K inhibitors to enhance cancer therapy. Future work should therefore also explore the effects of PI3K inhibitors on the tumor stroma, in addition to their cancer cell–intrinsic impact. Significance: The PI3K pathway extends beyond the direct regulation of cancer cell proliferation and survival. In B-cell malignancies, targeting PI3K purges the tumor cells from their protective microenvironment. Moreover, we propose that PI3K isoform–selective inhibitors may be exploited in the context of cancer immunotherapy and by targeting angiogenesis to improve drug and immune cell delivery. Cancer Discov; 6(10); 1090–105. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Basic and Therapeutic Aspects of Angiogenesis
Potente, M., Gerhardt, H., & Carmeliet, P. (2011) · Cell · doi:10.1016/j.cell.2011.08.039 · Cited by 2,771
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
Angiogenesis: an organizing principle for drug discovery?
Folkman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2115 · Cited by 2,246
Cancer immunotherapy via dendritic cells
Palucka, K., & Banchereau, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3258 · Cited by 2,049
A human memory T cell subset with stem cell–like properties
Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C. M., Quigley, M. F., Almeida, J. R., Gostick, E., Yu, Z., Carpenito, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2446 · Cited by 1,974
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315226 · Cited by 1,710
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
Ebos, J. M. L., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.021 · Cited by 1,709
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
Carmeliet, P., & Jain, R. K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3455 · Cited by 1,675
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
Davis, R. E., Ngo, V. N., Lenz, G., Tolar, P., Young, R. M., Romesser, P. B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., et al. (2010) · Nature · doi:10.1038/nature08638 · Cited by 1,643
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
mTOR regulates memory CD8 T-cell differentiation
Araki, K., Turner, A. P., Shaffer, V. O., Gangappa, S., Keller, S. A., Bachmann, M. F., Larsen, C. P., & Ahmed, R. (2009) · Nature · doi:10.1038/nature08155 · Cited by 1,575
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Thorpe, L. M., Yuzugullu, H., & Zhao, J. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3860 · Cited by 1,345
Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
Carver, B. S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, S., Arora, V. K., Le, C., Koutcher, J., Scher, H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.008 · Cited by 1,198
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation
Winkler, F., Kozin, S. V., Tong, R. T., Chae, S.-S., Booth, M. F., Garkavtsev, I., Xu, L., Hicklin, D. J., Fukumura, D., di Tomaso, E., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.011 · Cited by 1,170
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Gopal, A. K., Kahl, B. S., de Vos, S., Wagner-Johnston, N. D., Schuster, S. J., Jurczak, W. J., Flinn, I. W., Flowers, C. R., Martin, P., Viardot, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314583 · Cited by 1,069
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
Jain, R. K., Duda, D. G., Clark, J. W., & Loeffler, J. S. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0403 · Cited by 1,039
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Pfirschke, C., Engblom, C., Rickelt, S., Cortez-Retamozo, V., Garris, C., Pucci, F., Yamazaki, T., Poirier-Colame, V., Newton, A., Redouane, Y., et al. (2016) · Immunity · doi:10.1016/j.immuni.2015.11.024 · Cited by 952
Impaired B and T Cell Antigen Receptor Signaling in p110δ PI 3-Kinase Mutant Mice
Okkenhaug, K., Bilancio, A., Farjot, G., Priddle, H., Sancho, S., Peskett, E., Pearce, W., Meek, S. E., Salpekar, A., Waterfield, M. D., et al. (2002) · Science · doi:10.1126/science.1073560 · Cited by 946
Self-citationMorris, J. Z., Tissenbaum, H. A., & Ruvkun, G. (1996) · Nature · doi:10.1038/382536a0 · Cited by 891
The PI3K/AKT Pathway as a Target for Cancer Treatment
Mayer, I. A., & Arteaga, C. L. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-062913-051343 · Cited by 822
Subclonal diversification of primary breast cancer revealed by multiregion sequencing
Yates, L. R., Gerstung, M., Knappskog, S., Desmedt, C., Gundem, G., Van Loo, P., Aas, T., Alexandrov, L. B., Larsimont, D., Davies, H., et al. (2015) · Nature Medicine · doi:10.1038/nm.3886 · Cited by 816
Mazzone, M., Dettori, D., Leite de Oliveira, R., Loges, S., Schmidt, T., Jonckx, B., Tian, Y.-M., Lanahan, A. A., Pollard, P., Ruiz de Almodovar, C., et al. (2009) · Cell · doi:10.1016/j.cell.2009.01.020 · Cited by 812
Development of PI3K inhibitors: lessons learned from early clinical trials
Rodon, J., Dienstmann, R., Serra, V., & Tabernero, J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.10 · Cited by 766
Ebert, P. J. R., Cheung, J., Yang, Y., McNamara, E., Hong, R., Moskalenko, M., Gould, S. E., Maecker, H., Irving, B. A., Kim, J. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.024 · Cited by 713
Shrimali, R. K., Yu, Z., Theoret, M. R., Chinnasamy, D., Restifo, N. P., & Rosenberg, S. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0153 · Cited by 677
Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
Huang, Y., Goel, S., Duda, D. G., Fukumura, D., & Jain, R. K. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4354 · Cited by 669
Ibrahim, Y. H., García-García, C., Serra, V., He, L., Torres-Lockhart, K., Prat, A., Anton, P., Cozar, P., Guzmán, M., Grueso, J., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0348 · Cited by 601
Binding of Ras to Phosphoinositide 3-Kinase p110α Is Required for Ras- Driven Tumorigenesis in Mice
Gupta, S., Ramjaun, A. R., Haiko, P., Wang, Y., Warne, P. H., Nicke, B., Nye, E., Stamp, G., Alitalo, K., & Downward, J. (2007) · Cell · doi:10.1016/j.cell.2007.03.051 · Cited by 589
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Juric, D., Castel, P., Griffith, M., Griffith, O. L., Won, H. H., Ellis, H., Ebbesen, S. H., Ainscough, B. J., Ramu, A., Iyer, G., et al. (2015) · Nature · doi:10.1038/nature13948 · Cited by 588
Piccart, M., Hortobagyi, G. N., Campone, M., Pritchard, K. I., Lebrun, F., Ito, Y., Noguchi, S., Perez, A., Rugo, H. S., Deleu, I., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu456 · Cited by 574 · cited 1×
“6 month prolongation in PFS by the combination of everolimus (a rapamycin analog that inhibits mTORC1) with emestane (an aromatase inhibitor that blocks estrogen production) in the same breast cancer setting did not result in an overall survival benefit (30).”
BackgroundVascular normalization in Rgs5-deficient tumours promotes immune destruction
Hamzah, J., Jugold, M., Kiessling, F., Rigby, P., Manzur, M., Marti, H. H., Rabie, T., Kaden, S., Gröne, H.-J., Hämmerling, G. J., et al. (2008) · Nature · doi:10.1038/nature06868 · Cited by 564
Hoellenriegel, J., Meadows, S. A., Sivina, M., Wierda, W. G., Kantarjian, H., Keating, M. J., Giese, N., O'Brien, S., Yu, A., Miller, L. L., et al. (2011) · Blood · doi:10.1182/blood-2011-05-352492 · Cited by 549
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
Ali, K., Soond, D. R., Piñeiro, R., Hagemann, T., Pearce, W., Lim, E. L., Bouabe, H., Scudamore, C. L., Hancox, T., Maecker, H., et al. (2014) · Nature · doi:10.1038/nature13444 · Cited by 529
Self-citationPI3K-mediated negative feedback regulation of IL-12 production in DCs
Fukao, T., Tanabe, M., Terauchi, Y., Ota, T., Matsuda, S., Asano, T., Kadowaki, T., Takeuchi, T., & Koyasu, S. (2002) · Nature Immunology · doi:10.1038/ni825 · Cited by 529
Jiang, B.-H., Zheng, J. Z., Aoki, M., & Vogt, P. K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.040560897 · Cited by 528
Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration
Graupera, M., Guillermet-Guibert, J., Foukas, L. C., Phng, L.-K., Cain, R. J., Salpekar, A., Pearce, W., Meek, S., Millan, J., Cutillas, P. R., et al. (2008) · Nature · doi:10.1038/nature06892 · Cited by 520
Self-citationFritsch, C., Huang, A., Chatenay-Rivauday, C., Schnell, C., Reddy, A., Liu, M., Kauffmann, A., Guthy, D., Erdmann, D., De Pover, A., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0865 · Cited by 501
Pten in stromal fibroblasts suppresses mammary epithelial tumours
Trimboli, A. J., Cantemir-Stone, C. Z., Li, F., Wallace, J. A., Merchant, A., Creasap, N., Thompson, J. C., Caserta, E., Wang, H., Chong, J.-L., et al. (2009) · Nature · doi:10.1038/nature08486 · Cited by 500
Izcue, A., Coombes, J. L., & Powrie, F. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00423.x · Cited by 474
Targeting T Cell Co-receptors for Cancer Therapy
Callahan, M. K., Postow, M. A., & Wolchok, J. D. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.023 · Cited by 469
Juvekar, A., Burga, L. N., Hu, H., Lunsford, E. P., Ibrahim, Y. H., Balmañà, J., Rajendran, A., Papa, A., Spencer, K., Lyssiotis, C. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0336 · Cited by 465
Signaling by the Phosphoinositide 3-Kinase Family in Immune Cells
Okkenhaug, K. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095946 · Cited by 446
Self-citationClayton, E., Bardi, G., Bell, S. E., Chantry, D., Downes, C. P., Gray, A., Humphries, L. A., Rawlings, D., Reynolds, H., Vigorito, E., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020805 · Cited by 446
Bosch, A., Li, Z., Bergamaschi, A., Ellis, H., Toska, E., Prat, A., Tao, J. J., Spratt, D. E., Viola-Villegas, N. T., Castel, P., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4442 · Cited by 432
Tumor Vessel Normalization by Chloroquine Independent of Autophagy
Maes, H., Kuchnio, A., Peric, A., Moens, S., Nys, K., De Bock, K., Quaegebeur, A., Schoors, S., Georgiadou, M., Wouters, J., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.06.025 · Cited by 410
PI3Kδ and PI3Kγ: partners in crime in inflammation in rheumatoid arthritis and beyond?
Rommel, C., Camps, M., & Ji, H. (2007) · Nature Reviews Immunology · doi:10.1038/nri2036 · Cited by 398
Staron, M. M., Gray, S. M., Marshall, H. D., Parish, I. A., Chen, J. H., Perry, C. J., Cui, G., Li, M. O., & Kaech, S. M. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.013 · Cited by 385
Schmid, M. C., Avraamides, C. J., Dippold, H. C., Franco, I., Foubert, P., Ellies, L. G., Acevedo, L. M., Manglicmot, J. R. E., Song, X., Wrasidlo, W., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.016 · Cited by 378
Jou, S.-T., Carpino, N., Takahashi, Y., Piekorz, R., Chao, J.-R., Carpino, N., Wang, D., & Ihle, J. N. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.24.8580-8591.2002 · Cited by 357
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity
Van Keymeulen, A., Lee, M. Y., Ousset, M., Brohée, S., Rorive, S., Giraddi, R. R., Wuidart, A., Bouvencourt, G., Dubois, C., Salmon, I., et al. (2015) · Nature · doi:10.1038/nature14665 · Cited by 354
Somatic Activating PIK3CA Mutations Cause Venous Malformation
Limaye, N., Kangas, J., Mendola, A., Godfraind, C., Schlögel, M. J., Helaers, R., Eklund, L., Boon, L. M., & Vikkula, M. (2015) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2015.11.011 · Cited by 351
Crompton, J. G., Sukumar, M., Roychoudhuri, R., Clever, D., Gros, A., Eil, R. L., Tran, E., Hanada, K.-I., Yu, Z., Palmer, D. C., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2277 · Cited by 345
PIK3CAH1047R induces multipotency and multi-lineage mammary tumours
Koren, S., Reavie, L., Couto, J. P., De Silva, D., Stadler, M. B., Roloff, T., Britschgi, A., Eichlisberger, T., Kohler, H., Aina, O., et al. (2015) · Nature · doi:10.1038/nature14669 · Cited by 327
Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression
Kaneda, M. M., Cappello, P., Nguyen, A. V., Ralainirina, N., Hardamon, C. R., Foubert, P., Schmid, M. C., Sun, P., Mose, E., Bouvet, M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1346 · Cited by 326
BACH2 regulates CD8+ T cell differentiation by controlling access of AP-1 factors to enhancers
Roychoudhuri, R., Clever, D., Li, P., Wakabayashi, Y., Quinn, K. M., Klebanoff, C. A., Ji, Y., Sukumar, M., Eil, R. L., Yu, Z., et al. (2016) · Nature Immunology · doi:10.1038/ni.3441 · Cited by 325
Self-citationMayer, I. A., Abramson, V. G., Formisano, L., Balko, J. M., Estrada, M. V., Sanders, M. E., Juric, D., Solit, D., Berger, M. F., Won, H. H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0134 · Cited by 319
Patton, D. T., Garden, O. A., Pearce, W. P., Clough, L. E., Monk, C. R., Leung, E., Rowan, W. C., Sancho, S., Walker, L. S. K., Vanhaesebroeck, B., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.6598 · Cited by 303
Self-citationKrop, I. E., Mayer, I. A., Ganju, V., Dickler, M., Johnston, S., Morales, S., Yardley, D. A., Melichar, B., Forero-Torres, A., Lee, S. C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00106-6 · Cited by 295
Burger, J. A., & Gribben, J. G. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.08.011 · Cited by 285
Lampson, B. L., Kasar, S. N., Matos, T. R., Morgan, E. A., Rassenti, L., Davids, M. S., Fisher, D. C., Freedman, A. S., Jacobson, C. A., Armand, P., et al. (2016) · Blood · doi:10.1182/blood-2016-03-707133 · Cited by 285
Hori, S., Carvalho, T. L., & Demengeot, J. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200205)32:5<1282::aid-immu1282>3.0.co;2-# · Cited by 282
Management of adverse events associated with idelalisib treatment: expert panel opinion
Coutré, S. E., Barrientos, J. C., Brown, J. R., de Vos, S., Furman, R. R., Keating, M. J., Li, D., O’Brien, S. M., Pagel, J. M., Poleski, M. H., et al. (2015) · Leukemia & Lymphoma · doi:10.3109/10428194.2015.1022770 · Cited by 273
Macintyre, A. N., Finlay, D., Preston, G., Sinclair, L. V., Waugh, C. M., Tamas, P., Feijoo, C., Okkenhaug, K., & Cantrell, D. A. (2011) · Immunity · doi:10.1016/j.immuni.2011.01.012 · Cited by 273
Self-citationTolaney, S. M., Boucher, Y., Duda, D. G., Martin, J. D., Seano, G., Ancukiewicz, M., Barry, W. T., Goel, S., Lahdenrata, J., Isakoff, S. J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518808112 · Cited by 258
Schwartz, S., Wongvipat, J., Trigwell, C. B., Hancox, U., Carver, B. S., Rodrik-Outmezguine, V., Will, M., Yellen, P., de Stanchina, E., Baselga, J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.008 · Cited by 246
O'Brien, S. M., Lamanna, N., Kipps, T. J., Flinn, I., Zelenetz, A. D., Burger, J. A., Keating, M., Mitra, S., Holes, L., Yu, A. S., et al. (2015) · Blood · doi:10.1182/blood-2015-03-630947 · Cited by 241
cKit Lineage Hemogenic Endothelium-Derived Cells Contribute to Mesenteric Lymphatic Vessels
Stanczuk, L., Martinez-Corral, I., Ulvmar, M. H., Zhang, Y., Laviña, B., Fruttiger, M., Adams, R. H., Saur, D., Betsholtz, C., Ortega, S., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.02.026 · Cited by 238
Self-citationBusaidy, N. L., Farooki, A., Dowlati, A., Perentesis, J. P., Dancey, J. E., Doyle, L. A., Brell, J. M., & Siu, L. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.7356 · Cited by 231
ten Hacken, E., & Burger, J. A. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.07.009 · Cited by 229
Dual-Action Combination Therapy Enhances Angiogenesis while Reducing Tumor Growth and Spread
Wong, P.-P., Demircioglu, F., Ghazaly, E., Alrawashdeh, W., Stratford, M. R. L., Scudamore, C. L., Cereser, B., Crnogorac-Jurcevic, T., McDonald, S., Elia, G., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.10.015 · Cited by 223
Somatic PIK3CA mutations as a driver of sporadic venous malformations
Castel, P., Carmona, F. J., Grego-Bessa, J., Berger, M. F., Viale, A., Anderson, K. V., Bague, S., Scaltriti, M., Antonescu, C. R., Baselga, E., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf1164 · Cited by 216
Okkenhaug, K., Patton, D. T., Bilancio, A., Garçon, F., Rowan, W. C., & Vanhaesebroeck, B. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.8.5122 · Cited by 205
Self-citationPI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis
Fang, J., Ding, M., Yang, L., Liu, L.-Z., & Jiang, B.-H. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.07.025 · Cited by 205
Costa, C., Ebi, H., Martini, M., Beausoleil, S. A., Faber, A. C., Jakubik, C. T., Huang, A., Wang, Y., Nishtala, M., Hall, B., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.007 · Cited by 203
Soond, D. R., Bjørgo, E., Moltu, K., Dale, V. Q., Patton, D. T., Torgersen, K. M., Galleway, F., Twomey, B., Clark, J., Gaston, J. S. H., et al. (2010) · Blood · doi:10.1182/blood-2009-07-232330 · Cited by 195
Self-citationWill, M., Qin, A. C. R., Toy, W., Yao, Z., Rodrik-Outmezguine, V., Schneider, C., Huang, X., Monian, P., Jiang, X., de Stanchina, E., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0611 · Cited by 193
Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans
Castillo, S. D., Tzouanacou, E., Zaw-Thin, M., Berenjeno, I. M., Parker, V. E. R., Chivite, I., Milà-Guasch, M., Pearce, W., Solomon, I., Angulo-Urarte, A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad9982 · Cited by 192
Self-citationGraded Foxo1 activity in Treg cells differentiates tumour immunity from spontaneous autoimmunity
Luo, C. T., Liao, W., Dadi, S., Toure, A., & Li, M. O. (2016) · Nature · doi:10.1038/nature16486 · Cited by 187
Aksoy, E., Taboubi, S., Torres, D., Delbauve, S., Hachani, A., Whitehead, M. A., Pearce, W. P., Berenjeno, I. M., Nock, G., Filloux, A., et al. (2012) · Nature Immunology · doi:10.1038/ni.2426 · Cited by 185
Self-citationSchnell, C. R., Stauffer, F., Allegrini, P. R., O'Reilly, T., McSheehy, P. M. J., Dartois, C., Stumm, M., Cozens, R., Littlewood-Evans, A., García-Echeverría, C., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1044 · Cited by 174
The PTEN pathway in T regs is a critical driver of the suppressive tumor microenvironment
Sharma, M. D., Shinde, R., McGaha, T. L., Huang, L., Holmgaard, R. B., Wolchok, J. D., Mautino, M. R., Celis, E., Sharpe, A. H., Francisco, L. M., et al. (2015) · Science Advances · doi:10.1126/sciadv.1500845 · Cited by 171
The interplay of effector and regulatory T cells in cancer
Roychoudhuri, R., Eil, R. L., & Restifo, N. P. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.02.003 · Cited by 168
Wei, W., Shin, Y. S., Xue, M., Matsutani, T., Masui, K., Yang, H., Ikegami, S., Gu, Y., Herrmann, K., Johnson, D., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.012 · Cited by 168
Selective Inhibition of Regulatory T Cells by Targeting the PI3K–Akt Pathway
Eid, R. A., Samara, R. N., Ozbun, L. L., Abdalla, M. Y., Berzofsky, J. A., Friedman, K. M., Mkrtichyan, M., & Khleif, S. N. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0095 · Cited by 167
Activity of any class IA PI3K isoform can sustain cell proliferation and survival
Foukas, L. C., Berenjeno, I. M., Gray, A., Khwaja, A., & Vanhaesebroeck, B. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906461107 · Cited by 166
Self-citationIdelalisib in the management of lymphoma
Cheah, C. Y., & Fowler, N. H. (2016) · Blood · doi:10.1182/blood-2016-02-702761 · Cited by 162
Idelalisib-associated Colitis: Histologic Findings in 14 Patients
Weidner, A.-S., Panarelli, N. C., Geyer, J. T., Bhavsar, E. B., Furman, R. R., Leonard, J. P., Jessurun, J., & Yantiss, R. K. (2015) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000522 · Cited by 160
Molecules in medicine mini-review: isoforms of PI3K in biology and disease
Vanhaesebroeck, B., Whitehead, M. A., & Piñeiro, R. (2015) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1352-5 · Cited by 158
Self-citationIntratumoral Myeloid Cells Regulate Responsiveness and Resistance to Antiangiogenic Therapy
Rivera, L. B., Meyronet, D., Hervieu, V., Frederick, M. J., Bergsland, E. K., & Bergers, G. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.055 · Cited by 151
Tumor Vascular Changes Mediated by Inhibition of Oncogenic Signaling
Qayum, N., Muschel, R. J., Im, J. H., Balathasan, L., Koch, C. J., Patel, S. K., McKenna, W. G., & Bernhard, E. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0657 · Cited by 151
Boscolo, E., Coma, S., Luks, V. L., Greene, A. K., Klagsbrun, M., Warman, M. L., & Bischoff, J. E. (2014) · Angiogenesis · doi:10.1007/s10456-014-9453-2 · Cited by 149
Fokas, E., Im, J. H., Hill, S. A., Yameen, S., Stratford, M. R. L., Beech, J. S., Hackl, W., Maira, S.-M., Bernhard, E. J., McKenna, W. G., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2263 · Cited by 145
Barr, P. M., Saylors, G. B., Spurgeon, S. E. F., Cheson, B. D., Greenwald, D. R., O'Brien, S. M., Liem, A. K. D., Mclntyre, R. E., Joshi, A., Abella-Dominicis, E., et al. (2016) · Blood · doi:10.1182/blood-2015-12-683516 · Cited by 143
Idelalisib-associated Enterocolitis
Louie, C. Y., DiMaio, M. A., Matsukuma, K. E., Coutre, S. E., Berry, G. J., & Longacre, T. A. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000525 · Cited by 136
Brachmann, S. M., Kleylein-Sohn, J., Gaulis, S., Kauffmann, A., Blommers, M. J. J., Kazic-Legueux, M., Laborde, L., Hattenberger, M., Stauffer, F., Vaxelaire, J., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-1021 · Cited by 133
Iyengar, S., Clear, A. J., Bödör, C., Maharaj, L., Lee, A. R. I., Calaminici, M., Matthews, J., Iqbal, S., Auer, R. L., Gribben, J. G., et al. (2013) · Blood · doi:10.1182/blood-2012-10-460832 · Cited by 123
The phosphoinositide 3-kinase pathway and therapy resistance in cancer
Brown, K., & Toker, A. (2015) · F1000Prime Reports · doi:10.12703/p7-13 · Cited by 121
van der Waart, A. B., van de Weem, N. M. P., Maas, F., Kramer, C. S. M., Kester, M. G. D., Falkenburg, J. H. F., Schaap, N. P., Jansen, J. H., van der Voort, R., Gattinoni, L., et al. (2014) · Blood · doi:10.1182/blood-2014-05-578583 · Cited by 116
Class 1A PI3K regulates vessel integrity during development and tumorigenesis
Yuan, T. L., Choi, H. S., Matsui, A., Benes, C. H., Lifshits, E., Luo, J., Frangioni, J. V., & Cantley, L. C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804123105 · Cited by 112
Os, A., Bürgler, S., Parente-Ribes, A., Funderud, A., Wang, D., Thompson, K. M., Tjønnfjord, G. E., Bogen, B., & Munthe, L. A. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.07.011 · Cited by 112
Marques, R. B., Aghai, A., de Ridder, C. M. A., Stuurman, D. C., Hoeben, S. A. H., Boer, A., Ellston, R. P. A., Barry, S. T., Davies, B. R., Trapman, J., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.08.053 · Cited by 108
Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer
Weigelt, B., & Downward, J. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00109 · Cited by 102
The PI3K p110δ Regulates Expression of CD38 on Regulatory T Cells
Patton, D. T., Wilson, M. D., Rowan, W. C., Soond, D. R., & Okkenhaug, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017359 · Cited by 102
Self-citationPI3Kα activates integrin α4β1 to establish a metastatic niche in lymph nodes
Garmy-Susini, B. H., Avraamides, C. J., Desgrosellier, J. S., Schmid, M. C., Foubert, P., Ellies, L. G., Lowy, A. M., Blair, S. L., VandenBerg, S. R., Datnow, B., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219603110 · Cited by 99
Marshall, N. A., Galvin, K. C., Corcoran, A.-M. B., Boon, L., Higgs, R., & Mills, K. H. G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0307 · Cited by 96
Jiang, X., Chen, S., Asara, J. M., & Balk, S. P. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.085696 · Cited by 94
Uno, J. K., Rao, K. N., Matsuoka, K., Sheikh, S. Z., Kobayashi, T., Li, F., Steinbach, E. C., Sepulveda, A. R., Vanhaesebroeck, B., Sartor, R. B., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.07.008 · Cited by 94
Self-citationRAS interaction with PI3K p110α is required for tumor-induced angiogenesis
Murillo, M. M., Zelenay, S., Nye, E. L., Castellano, E., Lassailly, F., Stamp, G., & Downward, J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74134 · Cited by 89
Liu, D., Zhang, T., Marshall, A. J., Okkenhaug, K., Vanhaesebroeck, B., & Uzonna, J. E. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901099 · Cited by 89
Self-citationZhu, Q., Youn, H., Tang, J., Tawfik, O. W., Dennis, K. L., Terranova, P. F., Du, J., Raynal, P., Thrasher, J. B., & Li, B. (2008) · Oncogene · doi:10.1038/onc.2008.91 · Cited by 80
Regulation of angiogenesis and tumor growth by p110 Alpha and AKT1 via VEGF expression
Xia, C., Meng, Q., Cao, Z., Shi, X., & Jiang, B. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20707 · Cited by 80
Inhibition of the p110α isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis
Soler, A., Serra, H., Pearce, W. P., Angulo‐Urarte, A., Guillermet‐Guibert, J., Friedman, L. S., Viñals, F., Gerhardt, H., Casanovas, O., Graupera, M., et al. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20121571 · Cited by 80
Self-citationPI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL)
Okkenhaug, K., & Burger, J. A. (2015) · Current topics in microbiology and immunology · doi:10.1007/82_2015_484 · Cited by 78
Self-citationPI3K in cancer–stroma interactions: bad in seed and ugly in soil
Hirsch, E., Ciraolo, E., Franco, I., Ghigo, A., & Martini, M. (2013) · Oncogene · doi:10.1038/onc.2013.265 · Cited by 77
Fu, X., Creighton, C. J., Biswal, N. C., Kumar, V., Shea, M. J., Herrera, S., Contreras, A., Gutiérrez, C., Wang, T., Nanda, S., et al. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0430-x · Cited by 76
Schmid, M. C., Franco, I., Kang, S. W., Hirsch, E., Quilliam, L. A., & Varner, J. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060226 · Cited by 69
Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor
Kong, D., Okamura, M., Yoshimi, H., & Yamori, T. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.12.007 · Cited by 68
ErbB3 downregulation enhances luminal breast tumor response to antiestrogens
Morrison, M. M., Hutchinson, K. E., Williams, M. M., Stanford, J. C., Balko, J. M., Young, C. D., Kuba, M. G., Sanchez, V. M., Williams, A. J., Hicks, D. J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66764 · Cited by 66
The transcription factor BACH2 promotes tumor immunosuppression
Roychoudhuri, R., Eil, R. L., Clever, D. C., Klebanoff, C. A., Sukumar, M., Grant, F. M., Yu, Z., Mehta, G. U., Liu, H., Jin, P., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci82884 · Cited by 63
Self-citationHu, L., Hofmann, J., & Jaffe, R. B. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0206 · Cited by 62
Innate PI3K p110δ Regulates Th1/Th17 Development and Microbiota-Dependent Colitis
Steinbach, E. C., Kobayashi, T., Russo, S. M., Sheikh, S. Z., Gipson, G. R., Kennedy, S. T., Uno, J. K., Mishima, Y., Borst, L. B., Liu, B., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301533 · Cited by 57
Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics
Josephs, D. H., & Sarker, D. (2015) · Translational Oncogenomics · doi:10.4137/tog.s30529 · Cited by 54
Eid, R. A., Friedman, K. M., Mkrtichyan, M., Walens, A., King, W. C., Janik, J. E., & Khleif, S. N. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1005448 · Cited by 53
Bürgler, S., Gimeno, A., Parente-Ribes, A., Wang, D., Os, A., Devereux, S., Jebsen, P., Bogen, B., Tjønnfjord, G. E., & Munthe, L. A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401350 · Cited by 53
Inositol Phospholipid Signaling and the Biology of Natural Killer Cells
Kerr, W. G., & Colucci, F. (2011) · Journal of Innate Immunity · doi:10.1159/000323920 · Cited by 50
Qayum, N., Im, J. H., Stratford, M. R. L., Bernhard, E. J., McKenna, W. G., & Muschel, R. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1413 · Cited by 48
Leukemic challenge unmasks a requirement for PI3Kδ in NK cell–mediated tumor surveillance
Zebedin, E., Simma, O., Schuster, C., Putz, E. M., Fajmann, S., Warsch, W., Eckelhart, E., Stoiber, D., Weisz, E., Schmid, J. A., et al. (2008) · Blood · doi:10.1182/blood-2008-02-139105 · Cited by 44
González-García, A., Sánchez-Ruíz, J., Flores, J. M., & Carrera, A. C. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.12.001 · Cited by 44
Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors
Soler, A., Figueiredo, A. M., Castel, P., Martin, L., Monelli, E., Angulo‐Urarte, A., Milà‐Guasch, M., Viñals, F., Baselga, J. M., Casanovas, O., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3051 · Cited by 43
Self-citationPI3K at the crossroads of tumor angiogenesis signaling pathways
Soler, A., Angulo‐Urarte, A., & Graupera, M. (2015) · Molecular & Cellular Oncology · doi:10.4161/23723556.2014.975624 · Cited by 39
Self-citationSoond, D. R., Garçon, F., Patton, D. T., Rolf, J., Turner, M., Scudamore, C. L., Garden, O. A., & Okkenhaug, K. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102116 · Cited by 38
Self-citationPI3Kδ Regulates the Magnitude of CD8+ T Cell Responses after Challenge with Listeria monocytogenes
Pearce, V. Q., Bouabe, H., MacQueen, A. R., Carbonaro, V., & Okkenhaug, K. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1501227 · Cited by 36
Self-citationPI3Kδ Is Essential for Tumor Clearance Mediated by Cytotoxic T Lymphocytes
Putz, E. M., Prchal‐Murphy, M., Simma, O., Forster, F., Koenig, X., Stockinger, H. S. J., Piekorz, R. P., Freissmuth, M., Müller, M. M., Sexl, V., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040852 · Cited by 35
Yang, W., Hosford, S. R., Dillon, L. M., Shee, K., Liu, S. C., Bean, J. R., Salphati, L., Pang, J., Zhang, X., Nannini, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2276 · Cited by 34
Pharmacology in the Era of Targeted Therapies: The Case of PI3K Inhibitors
Toska, E., & Baselga, J. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0038 · Cited by 34
Gracias, D. T., Boesteanu, A. C., Fraietta, J. A., Hope, J. L., Carey, A. J., Mueller, Y. M., Kawalekar, O. U., Fike, A. J., June, C. H., & Katsikis, P. D. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501890 · Cited by 28
IDENTIFICATION OF A PHOSPHOINOSITIDE 3-KINASE (PI-3K) P110DELTA (PIK3CD) DEFICIENT INDIVIDUAL
Jordan, M. B. (2013) · 2013 CIS Annual Meeting: Regulation & Dysregulation of Immunity April 25 - 28, 2013 · Cited by 21
PI3K Inhibitor Improves PFS in BELLE-2 Trial
(2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2015-176 · Cited by 14
Doisne, J., Hüber, C. M., Okkenhaug, K., & Colucci, F. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.01.002 · Cited by 13
Self-citationLeake, I. (2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2014.97 · Cited by 9
Zotes, T. M., Spada, R., Mulens‐Arias, V., Pérez-Yagüe, S., Sorzano, C. Ó. S., Okkenhaug, K., Carrera, A. C., & Barber, D. F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072960 · Cited by 4
Self-citationBlouin, M., Birman, E., Zhao, Y., Zakikhani, M., & Pollak, M. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-4615 · Cited by 1
Cited by
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749
“Additionally, knowledge gained from mouse genetics has led to the concept that drugmediated inhibition of PI3K isoforms expressed in immune cells (p110g and p110d) can reprogram the immune system to combat solid tumor cells more effectively (Okkenhaug et al., 2016).”
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Targeting PI3K/Akt signal transduction for cancer therapy
He, Y., Sun, M. M., Zhang, G. G., Yang, J., Chen, K. S., Xu, W. W., & Li, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00828-5 · Cited by 1,892
PI3K isoforms in cell signalling and vesicle trafficking
Bilanges, B., Posor, Y., & Vanhaesebroeck, B. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0129-z · Cited by 525
Self-citationCell motility in cancer invasion and metastasis: insights from simple model organisms
Stuelten, C. H., Parent, C. A., & Montell, D. J. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2018.15 · Cited by 519
Metadata
- Authors
- Okkenhaug, K., Graupera, M., & Vanhaesebroeck, B.
- Venue
- Cancer Discovery
- Published
- 2016-10-01
- Volume
- 6
- Issue
- 10
- Pages
- 1090-1105
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2522884107
- Cited by
- 264
- References
- 158
- FWCI
- 12.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.